Skip to main content

Salvage Therapy and Palliative Care for Metastatic Sarcoma

  • Chapter
  • First Online:
Sarcoma

Abstract

The care of a patient with metastatic disease involves multiple disciplines. One individual must be the designated leader and always be accessible to the patient and/or family. The medical oncologist often utilizes salvage chemotherapy regimens that balance both quality of life and deceleration of the progression of disease. The radiation oncologist plays an important role with the delivery of radiation to painful sites for palliation, and to sites that require greater local control to slow the disease down. When the disease has spread to the spine, the orthopedist or neurosurgeon aids in preventing paralysis or neurologic pain. A mental health professional may be necessary to treat reactive depression in both the patient and any family members and involved caretakers. The primary care physician often knows the patient and family best and may assist in pain control and the general health of all involved. Above all, a member of the healthcare team must manage the patient’s pain. Although it may not be possible to cure the patient with metastatic sarcoma, all efforts should be made to control the patient’s pain and optimize a patient’s function for the remaining duration of their life.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Neglia JP, Friedman DL, Yasui Y, et al. Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study. J Natl Cancer Inst. 2001;93(8):618–29.

    Article  CAS  PubMed  Google Scholar 

  2. Dossett LA, Toloza EM, Fontaine J, et al. Outcomes and clinical predictors of improved survival in patients undergoing pulmonary metastasectomy for sarcoma. J Surg Oncol. 2015;112(1):103–6.

    Article  PubMed  Google Scholar 

  3. Matsubara E, Mori T, Koga T, et al. Metastasectomy of pulmonary metastases from osteosarcoma: prognostic factors and indication for repeat metastasectomy. J Resp Med. 2015;2015:570314. 5 pages

    Google Scholar 

  4. Kawaguchi S, Sun T, Lin PP, Deavers M, Harun N, Lewis VO. Does ifosfamide therapy improve survival of patients with dedifferentiated chondrosarcoma? Clin Orthop Relat Res. 2014;472(3):983–9.

    Article  PubMed  Google Scholar 

  5. Italiano A, Mir O, Cioffi A, et al. Advanced chondrosarcomas: role of chemotherapy and survival. Ann Oncol. 2013;24(11):2916–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Yousaf N, Harris S, Martin-Liberal J, et al. First-line palliative chemotherapy in elderly patients with advanced soft tissue sarcoma. Clin Sarcoma Res. 2015;5:10.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Karavasilis V, Seddon BM, Ashley S, et al. Significant clinical benefit of first-line palliative chemotherapy in advanced soft tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients. Cancer. 2008;112(7):1585–91.

    Article  PubMed  Google Scholar 

  8. Garbay D, Maki RG, Blay JY, et al. Advanced soft-tissue sarcoma in elderly patients: patterns of care and survival. Ann Oncol. 2013;24(7):1924–30.

    Article  CAS  PubMed  Google Scholar 

  9. Iwata S, Ishii T, Kawai A, et al. Prognostic factors in elderly osteosarcoma patients: a multi-institutional retrospective study of 86 cases. Ann Surg Oncol. 2014;21(1):263–8.

    Article  PubMed  Google Scholar 

  10. Bramwell VH, Anderson D, Charette ML. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft-tissue sarcoma: a meta-analysis and clinical practice guideline. Sarcoma. 2000;4(3):103–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Judson I, Verweij J, Gelderblom H, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomized controlled phase 3 trial. Lancet Oncol. 2014;15(4):415–23.

    Article  CAS  PubMed  Google Scholar 

  12. Dahlin DC, Coventry MB. Osteogenic sarcoma: a study of six hundred cases. J Bone Joint Surg Am. 1967;49(1):101–10.

    Article  CAS  PubMed  Google Scholar 

  13. Eilber F, Giuliano A, Eckhardt J, Patterson K, Moseley S, Goodnight J. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol. 1987;5(1):21–6.

    Article  CAS  PubMed  Google Scholar 

  14. Bacci G, Farrar S, Bertoni F, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Istituto Ortopedico Rizzoli according to the osteosarcoma-2 protocol: an updated report. J Clin Oncol. 2000;18(24):4016–27.

    Article  CAS  PubMed  Google Scholar 

  15. Maki RG. Ifosfamide in the neoadjuvant treatment of osteogenic sarcoma. J Clin Oncol. 2012;3(17):2033–5.

    Article  Google Scholar 

  16. Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003;348(8):694–701.

    Article  CAS  PubMed  Google Scholar 

  17. Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in Ewing’s tumor of bone: analysis of 975 patients from the European intergroup cooperative Ewing’s sarcoma study group. J Clin Oncol. 2000;18(17):3108–14.

    Article  CAS  PubMed  Google Scholar 

  18. Campanna R, Bertoni F, Bacchini P, Bacci G, Guerra A, Campanacci M. Malignant fibrous histiocytoma of bone. The experience at the Rizzoli institute: report of 90 cases. Cancer. 1984;54(1):177–87.

    Article  Google Scholar 

  19. Bramwell VH, Steward WP, Nooij M, Whelan J, Craft AW, Grimer RJ, et al. Neoadjuvant chemotherapy with doxorubicin and cisplatin in malignant fibrous histiocytoma of bone: a European osteosarcoma intergroup study. J Clin Oncol. 1999;17(10):3260–9.

    Article  CAS  PubMed  Google Scholar 

  20. Jeon DG, Song WS, Kong CB, Kim JR, Lee SY. MFH of bone and osteosarcoma show similar survival and chemosensitivity. Clin Orthop Relat Res. 2001;469(2):584–90.

    Article  Google Scholar 

  21. Navid F, Willert JR, McCarville MB, Furman W, Watkins A, Roberts W, Daw NC. Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer. 2008;113(2):419–25.

    Article  CAS  PubMed  Google Scholar 

  22. Casali PG, Picci P. Adjuvant chemotherapy for soft tissue sarcoma. Curr Opin Oncol. 2005;17(4):361–5.

    Article  CAS  PubMed  Google Scholar 

  23. Courmier JN, Pollock RE. Soft tissue sarcomas. CA Cancer J Clin. 2004;54(2):94–109.

    Article  Google Scholar 

  24. Sarcoma Meta-Analysis Collaboration. Adjuvant chemotherapy for localized resectable soft tissue sarcoma of adults: meta-analysis of individual data. Lancet. 1997;350(9092):1647–54.

    Article  Google Scholar 

  25. Patrikidou A, Domont J, Cioffi A, Le Cesne A. Treating soft tissue sarcomas with adjuvant chemotherapy. Curr Treat Options Oncol. 2012;17(8):515–27.

    Google Scholar 

  26. Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J Clin Oncol. 2007;25(19):2755–63.

    Article  CAS  PubMed  Google Scholar 

  27. Penel N, Bui BN, Bay JO, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma. J Clin Oncol. 2008;26(32):5269–74.

    Article  CAS  PubMed  Google Scholar 

  28. Rosen G, Forcher C, Lowenbraun S, et al. Synovial sarcoma: uniform response of metastases to high dose ifosfamide. Cancer. 1994;73(10):2506–11.

    Article  CAS  PubMed  Google Scholar 

  29. Arndt CA, Rose PS, Folpe AL, Laack NN. Common musculoskeletal tumors of childhood and adolescence. Mayo Clin Proc. 2012;87(5):475–87.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Okuno SH, Postel-Vinay S, Molife LR, Okuno SH, Schuetze SM, Paccagnella ML, et al. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing’s sarcoma: a phase 1 expansion cohort study. Lancet Oncol. 2010;11:129–35.

    Article  PubMed  Google Scholar 

  31. Dubois SG, Shusterman S, Ingle AM, Ahern CH, Reid JM, Wu B, et al. Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumours: a children’s oncology group study. Clin Cancer Res. 2001;17:5113–22.

    Article  Google Scholar 

  32. Keir ST, Morton CL, Wu J, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing of the multitargeted kinase inhibitor pazopanib by the pediatric preclinical testing program. Pediatr Blood Cancer. 2012;59:586–8.

    Article  PubMed  Google Scholar 

  33. Subbiah V, Wagner MJ, McGuire MF, et al. Personalized comprehensive molecular profiling of high risk osteosarcoma: implications and limitations for precision medicine. Oncotarget. 2015;6(38):40642–54.

    PubMed  PubMed Central  Google Scholar 

  34. Rahn DA, Mundt AJ, Murphy JD, Schiff D, Adams J, Murphy KT. Clinical outcomes of palliative radiation therapy for children. Pract Radiat Oncol. 2014;5(3):183–7.

    Article  PubMed  Google Scholar 

  35. Koontz BF, Clough RW, Halperin EC. Palliative radiation therapy for metastatic Ewing sarcoma. Cancer. 2006;106(8):1790–3.

    Article  PubMed  Google Scholar 

  36. Chung PW, Deheshi BM, Ferguson PC, Wunder JS, Griffin AM, Catton CN, Bell RS, White LM, Kandel RA, O’Sullivan BO. Radiosensitivity translates into excellent local control in extremity Myxoid liposarcoma. Cancer. 2009;115(14):3254–61.

    Article  PubMed  Google Scholar 

  37. Brown LC, Lester RA, Grams MP, Haddock MG, Olivier KR, Arndt CA, Rose PS, Laack NN. Stereotactic body radiotherapy for metastatic and recurrent Ewing sarcoma and osteosarcoma. Sarcoma. 2014;2014:418270.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Stragliotto CL, Karlsson K, Lax I, Rutkowska E, Bergh J, Strander H, Blomgren H, Friesland S. A retrospective study of SBRT of metastases in patients with primary sarcoma. Med Oncol. 2012;29(5):3431–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Dhakal S, Corbin KS, Milano MT, Philip A, Sahasrabudhe D, Jones C, Constine LS. Stereotactic body radiotherapy for pulmonary metastases from soft-tissue sarcomas: excellent local lesion control and improved patient survival. Int J Radiat Oncol Biol Phys. 2012;82(2):940–5.

    Article  PubMed  Google Scholar 

  40. Eisenhut M. Iodine-131-labeled diphosphonates for the palliative treatment of bone metastases: I. Organ distribution and kinetics of I-131 BDP3 in rats. J Nucl Med. 1984;25(12):1356–61.

    CAS  PubMed  Google Scholar 

  41. Blake GM, Zivanovic MA, McEwan AJ, Condon BR, Ackery DM. Strontium-89 therapy: strontium kinetics and dosimetry in two patients treated for metastasizing osteosarcoma. Br J Radiol. 1987;60(711):253–9.

    Article  CAS  PubMed  Google Scholar 

  42. Berger M, Grignani G, Giostra A, Ferrari S, Ferraresi V, et al. 153 samarium-EDTMP administration followed by hematopoietic stem cell support for bone metastases in osteosarcoma patients. Ann Oncol. 2012;23(7):1899–905.

    Article  CAS  PubMed  Google Scholar 

  43. Franzius C, Schuck A, Bielack SS. High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol. 2002;20(1):189–96.

    Article  Google Scholar 

  44. Anderson PM, Subbiah V, Rohren E. Bone-seeking radiopharmaceuticals as targeted agents of osteosarcoma: samarium-153-EDTMP and radium-223. Adv Exp Med Biol. 2014;804:291–304.

    Article  CAS  PubMed  Google Scholar 

  45. Mavrogenis AF, Ross G, Altimari G, Calabro T, Angelini A, Palmerini E, Rimondi E, Ruggieri P. Palliative embolization for advanced bone sarcomas. Radiol Med. 2013;118(8):1344–59.

    Article  CAS  PubMed  Google Scholar 

  46. Sanou R, Bazin C, Krakowski I, Boccaccini H, Mathias J, Beot S, Marchal F, Regent D. Radiofrequency ablation for palliation of soft tissue tumor pain. J Radiol. 2010;91(3):281–6.

    Article  CAS  PubMed  Google Scholar 

  47. Falk AT, Moureau-Zabotto L, Quali M, Penel N, Italiano A, Bay J, et al. Effect on survival of local ablative treatment of metastases from sarcomas: a study of the French sarcoma group. Clin Oncol. 2015;27(1):48–55.

    Article  CAS  Google Scholar 

  48. Bastianpillai C, Petrides N, Shah T, et al. Harnessing the immunomodulatory effect of thermal and non-thermal ablative therapies for cancer treatment. Tumour Biol. 2015;36(12):9137–46.

    Article  CAS  PubMed  Google Scholar 

  49. Clarencon F, Jean B, Pham HP, Cormier E, Bensimon G, Rose M, Maksud P, Chiras J. Value of percutaneous radiofrequency ablation with or without percutaneous vertebroplasty for pain relief and functional recover in painful bone metastases. Skeletal Radiol. 2013;42(1):25–36.

    Article  PubMed  Google Scholar 

  50. Aboulafia AJ, Levine AM, Schmidt D, Aboulafia D. Surgical therapy of bone metastases. Semin Oncol. 2007;34(3):206–14.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Matthew Wallace M.D., M.B.A. .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Wallace, M., Aboulafia, A. (2017). Salvage Therapy and Palliative Care for Metastatic Sarcoma. In: Henshaw, R. (eds) Sarcoma. Springer, Cham. https://doi.org/10.1007/978-3-319-43121-5_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-43121-5_13

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-43119-2

  • Online ISBN: 978-3-319-43121-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics